Phebra Pty Ltd – Trademark Portfolio

Entity Type: 03

Phebra Pty Ltd holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include PHEBRA.

19 Orion Road

Lane Cove West NSW 2066

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Phebra Pty Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Phebra Pty Ltd have?

Phebra Pty Ltd has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does Phebra Pty Ltd file in?

Phebra Pty Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Phebra Pty Ltd's most well-known trademarks?

Phebra Pty Ltd's registered trademark portfolio includes well-known marks such as PHEBRA. These are among 1 currently registered trademark in the portfolio.

What is Phebra Pty Ltd's trademark registration success rate?

Phebra Pty Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.